Gut Hormone Profiling in Obese Patients With Type 2 Diabetes (MK-0000-134)

Merck Sharp & Dohme LLC22 enrolled

Overview

This study will examine changes in various gut-derived hormones in obese type 2 diabetic patients before and after elective bariatric surgery.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Obesity, Morbid Diabetes Mellitus Type 2

Eligibility

Sex: ALLMin age: 20 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Documented type 2 diabetes with total disease duration ≤10 years * BMI of at least 35 kg/m\^2 * Patient is a surgical candidate for either RYGBP, GBS or vertical sleeve gastrectomy (VSG) Exclusion Criteria: * Any illness that might confound the results of the study or pose additional risk to the patient by participation * History of stroke, seizures, or other major neurological disorder * History of cancer * Patient uses or has used any medication that can alter body weight * Patient is unwilling or unable to follow study procedures

Outcomes

Primary Outcomes

Change from baseline in PYY (Peptide YY) measured by ELISA 4 weeks after RYGBP

Time frame: Baseline and Week 4

Secondary Outcomes

Change from baseline in PYY measured by dMS 4 weeks after RYGBP

Time frame: Baseline and week 4

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.